Maßgeschneiderte Lösungen für Ihre Herausforderungen in der pharmazeutischen Entwicklung
Unser Engagement und unsere Erfahrung in der pharmazeutischen Entwicklung machen uns zu Ihrem idealen Partner
Aktuelle News
Kester Capital backs management buy-out of Rephine
Rephine is delighted to announce the purchase of the business via a management buy-out, by a team comprising the existing senior managers together with a ...
Read More Getting Ready for the Clinical Trial Regulation
It’s been a difficult year for many biopharma companies and perhaps even more so for clinical research organisations, with Covid-19 forcing the postponement or even ...
Read More Medical Devices Back in the Spotlight
The global disruption caused by the pandemic meant regulatory plans for 2020 needed to be delayed to give the life sciences industry and authorities breathing ...
Read More Data protection to take centre stage in 2021
In early December, the EMA announced that it had been hit by a cyber-attack and that documents related to the Pfizer-BioNTech Covid-19 vaccines had been ...
Read More